| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.45 | 0.003 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.004 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | -0.078 | 0.004 |
| mRNA | darinaparsin | CTRPv2 | pan-cancer | AAC | 0.14 | 0.004 |
| mRNA | KU-55933 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | Obatoclax Mesylate | CTRPv2 | pan-cancer | AAC | -0.093 | 0.005 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.006 |